Various
therapies are used for
inflammatory bowel diseases (IBD), though none seem to be extremely effective.
AP-1 is a major
transcription factor that upregulates genes involved in immune and proinflammatory responses. We investigated decoy
oligodeoxynucleotide (ODN) targeting
AP-1 to prevent
dextran sulfate sodium (DSS)-induced
colitis in mice. Functional efficacies of synthetic decoy and scrambled ODNs were evaluated in vitro by a reporter gene
luciferase assay and measuring
flagellin-induced
IL-8 expression by HCT-15 cells transfected with ODNs. Experimental
colitis was induced in mice with a 2.5% DSS
solution in
drinking water for 7 days, and decoy or scrambled ODNs were intraperitoneally injected from days 2 to 5.
Colitis was assessed by
weight loss, colon length, histopathology, and detection of
myeloperoxidase (MPO), IL-1beta, and
TNF-alpha in colon tissue.
Therapeutic effects of
AP-1 and
NF-kappaB decoy ODNs were compared. Transfection of
AP-1 decoy ODN inhibited
AP-1 transcriptional activity in reporter assays and
flagellin-induced
IL-8 production in vitro. In mice,
AP-1 decoy ODN, but not scrambled ODN, significantly inhibited
weight loss, colon shortening, and histological
inflammation induced by DSS. Further,
AP-1 decoy ODN decreased MPO, IL-1beta, and
TNF-alpha in colonic tissue of mice with DSS-induced
colitis. The
AP-1 decoy
therapeutic effect was comparable to that of
NF-kappaB decoy ODN, which also significantly decreased intestinal
inflammation. Double-strand decoy ODN targeting
AP-1 effectively attenuated intestinal
inflammation associated with experimental
colitis in mice, indicating the potential of targeting proinflammatory
transcription factors in new
therapies for IBD.